FJ

Frederick Jones

Biopharma executive, consultant and investor

Wayne, Pennsylvania

Invests in

  • Min Investment:

    $1,500,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $3,250,000.00

Skills

CEO
Business Development
Business Strategy
Team Building
Biotechnology
Commercialization
Start-ups
Biochemistry
Mergers & Acquisitions
Drug Discovery
Due Diligence
Biopharmaceuticals
Clinical Development
Licensing
Corporate Development
Lifesciences
Drug Development
Pharmaceutical Industry
Strategy
R&D

Work Experience

  • Advisory Partner

    2024

    Outreach and deal flow generation. Government relations. Board representation. Opportunity reviews.

  • Partner

    2018 - 2024

    Source, diligence, negotiate and manage venture capital investments in early stage biotechnology companies.

3 Degree Consulting LLC

2024

  • Principal

    2024

    Strategic consulting and fractional executive for seed stage biopharma companies.

  • Director

    2014 - 2017

    Broadview Ventures is a philanthropic, for-profit venture fund supported by the Leducq Family Trust with a mission to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures

Independent Consultant

2012 - 2014

  • Business Development and Operations Professional

    2012 - 2014

    I apply my broad background, which includes practicing internal medicine, medical affairs, safety monitoring, business development and general management in large pharma and small biotech, in providing business development services, operational expertise and strategic guidance to early stage biotechnology companies. I have helped recruit technical experts, organize support functions, draft strategic plans, and make investor and collaboration pitches. My experience includes negotiating option and license agreements, guiding patent strategy, and identifying business partners. Recent projects include Roundhouse Therapeutics (Beth Israel/Harvard spinout developing small molecule and antibody modulators of Pin1 pathway for cancer and Alzheimer’s disease) and Spordiff Therapeutics (Tufts spinout developing small molecule inhibitors of Clostridium difficile spore germination).

  • CEO

    2008 - 2011

2007 - 2008

  • Head, Pharma Business Unit

    2007 - 2008

BioRexis (Pfizer)

2004 - 2007

  • VP, Business Development

    2004 - 2007

  • AVP, Global Business Development

    2000 - 2004

  • Sr. Director, Global Medical Affairs

    1997 - 2000

  • Assistant Professor, Division of General Internal Medicine

    1994 - 1997